Thomas Rocco Jr: Adverse Cardiovascular Outcomes Associated with Metabolic Syndrome in Non-Obese Patients with Heart Failure
Thomas Rocco Jr, Clinical Professor Emeritus of Medicine at University of Rochester Medical Center, shared a post on LinkedIn about a recent article by Daniel D Han et al, adding:
“The presence of metabolic abnormalities is a potent risk factor in heart failure, regardless of a patient’s weight; and this research article suggests clinicians should prioritize early metabolic screening and intervention for all cardiac patients, including those with a normal BMI.
A retrospective analysis, based on the MADIT-CRT database, revealed that even among non-obese patients, 57 percent met the criteria for Metabolic Syndrome (MS).
And non-obese patients with MS had a significantly higher 3-year cumulative probability of heart failure or death (34 percent) compared to those without MS (20 percent).
Further, within the non-obese MS group, those with Diabetes faced the highest risk, showing a 28 percent rate of adverse events within just 2.5 years.
Interestingly, ‘reverse cardiac remodeling’ was similar across all groups, suggesting that the increased risk in MS patients is driven by metabolic factors rather than a lack of response to device therapy (CRT/resynchronization therapy).
The lead author is a medical student at the University of Rochester School of Medicine and Dentistry.”
Title: Effects of Metabolic Syndrome on Cardiovascular Outcomes in Non-Obese Heart Failure Patients
Authors: Daniel D Han, Susanne Miedlich, Diane Morse, Robert Block, Wojciech Zareba, Ilan Goldenberg, Scott McNitt, Valentina Kutyifa
Read the Full Article on ESC Heart Failure.

Stay updated on all scientific advances with Hemostasis Today.
-
Jul 13, 2026, 17:39Pascal Boulanger: Send a Postcard to Your Lab Staff From ISTH 2026
-
Jul 13, 2026, 17:21Stefano Navarro: Presenting Our Recently Published Article at ISTH 2026
-
Jul 13, 2026, 17:12Santagata Davide: A Great Session and an Incredible Opportunity to Present Our Research at ISTH 2026
-
Jul 13, 2026, 16:26Real-World Data Across Time Reveal Important Advances in Hemophilia Treatment – ATHN
-
Jul 13, 2026, 16:19Mary Cushman: Celebrating Our Incredible ISTH Council Members in Paris
-
Jul 13, 2026, 16:17Wolfgang Miesbach: Gene Therapy Shows Promising Early Results in Adolescents With Hemophilia B at ISTH 2026
-
Jul 13, 2026, 16:06Dino Mehic: Honored to Receive the ISTH Early Career Top Reviewer Awards
-
Jul 13, 2026, 16:01Advancing DIC Diagnosis in Cirrhosis Through Disease-Specific Risk Stratification – JTH
-
Jul 13, 2026, 15:52Joshua Muia: Presenting Our Research on ADAMTS13/VWF Dysregulation in Sepsis at ISTH 2026